Novo’s Ozempic cuts risk of death by 20% in patients with diabetes, chronic kidney disease

24 May 2024
firstwordpharma.com
Clinical ResultAHAClinical Study
Results showed that Novo Nordisk’s Ozempic (semaglutide) cut the risk of death by 20% compared to placebo in people with type 2 diabetes and chronic kidney disease (CKD). The detailed findings from the FLOW trial were presented Friday at the European Renal Association (ERA) congress and published in The NEJM.
Study investigator Vlado Perkovic said the findings, which build on those top-lined in March, “offer great promise in reshaping treatment strategies for individuals at high risk of diabetes-related complications, offering a new avenue for kidney and cardiovascular protection.”
Novo Nordisk announced last October that the FLOW study achieved its primary endpoint, with a 1mg dose of Ozempic demonstrating a statistically significant and superior reduction in kidney disease progression, major adverse cardiovascular events (MACE) and death versus placebo. Results released earlier this year demonstrated that the GLP-1 analogue cut the risk of kidney disease-related events by 24% compared to placebo, with both CKD and cardiovascular components of the primary endpoint contributing to the risk reduction.
The latest results showed that as well as the reduction in all-cause mortality, Ozempic cut the risk of major cardiovascular events by 18% over placebo, while the total eGFR slope was 1.16 ml/min/1.73m2/year slower. In addition, for the primary endpoint, findings were similar for a composite of the kidney-specific components of the primary outcome, with a hazard ratio (HR). and for death from cardiovascular causes, with a HR of 0.71.
Perkovic remarked “these benefits signify a profound clinical impact saving kidneys, hearts and lives, for patients with type 2 diabetes and chronic kidney disease.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.